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Abstract (204 words) 1 
Adrenocortical carcinoma (ACC) is an orphan disease lacking effective systemic 2 
treatment options. The low incidence of the disease and high cost of clinical trials are 3 
major obstacles in the search for improved treatment strategies. As a novel approach, 4 
registry-based clinical trials have been introduced in clinical research, so allowing for 5 
significant cost reduction, but without compromising scientific benefit. Herein, we 6 
describe how the European Network for the Study of Adrenal Tumours (ENSAT) could 7 
transform its current registry into one fit for a clinical trial infrastructure. The rationale 8 
to perform randomized registry-based trials in ACC is outlined including an analysis of 9 
relevant limitations and challenges. We summarize a survey on this concept among 10 
ENSAT members who expressed a strong interest of the concept and rated its 11 
scientific potential as high. Legal aspects, including ethical approval of registry-based 12 
randomization were identified as potential obstacles. Finally, we describe three 13 
potential randomized registry-based clinical trials in an adjuvant setting and for 14 
advanced disease with a high potential to be executed within the framework of an 15 
advanced ENSAT registry. Thus we therefore provide the basis for future registry-16 
based trials for ACC patients. This could ultimately provide proof-of-principle of how to 17 
perform more effective randomized trials for an orphan disease.  18 
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Introduction 1 
Adrenocortical carcinoma (ACC) is a rare disease for which diagnostic approaches 2 
and therapeutic strategies have only gradually changed over the past decades (1, 2). 3 
Accordingly, the overall survival for patients diagnosed with ACC remains in the range 4 
of 3–4 years (3, 4). Affected patients also experience severe morbidity due to 5 
endocrine disturbances as well as tumour growth (1, 5, 6). In a recent review, we 6 
identified topics including disease prevention and earlier detection, improved risk-7 
stratification, controlling tumour growth and invasiveness as well as suppressing 8 
hormone production as unresolved problems that need to be addressed by research 9 
with the overarching aim to reduce ACC-related morbidity and mortality (1). 10 
While clinical trials have the potential to explore strategies to approach these problems, 11 
the current research infrastructure fails in providing effective resources to perform such 12 
projects on rare diseases. In this context, registry-based clinical trials have emerged 13 
as a resource-efficient alternative solution to address clinical and translational 14 
research questions (7-10). In this review, we aim to describe how registry-based trials 15 
could be used to advance care of patients with ACC. Furthermore, we argue that the 16 
European Network for the Study of Adrenal Tumours (ENSAT) is well positioned to 17 
transform its current registry and advance its strong collaboration to implement 18 
registry-based clinical trials. Finally, we propose potential research projects with 19 
potential to be executed within this space. 20 
 21 
Randomized clinical trials 22 
A randomized controlled trial provides the experimental framework that aims to 23 
evaluate the effectiveness and safety of a medical intervention. By randomly assigning 24 
patients between experimental and control arms, it ensures the greatest reliability and 25 
validity of the results, by reducing impact from both known and unrecognized bias. 26 
Appropriately executed (11), it is considered as the gold standard for evaluating 27 
healthcare interventions. In contrast, those medical practices that are based on 28 
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evidence from non-randomized controlled data are prone to bias and misinterpretation. 1 
Clinical trials lacking a control arm and those using historical controls have repeatedly 2 
been shown to exaggerate the efficacy of treatments (12). Similarly, early clinical trials 3 
on small or diverse patient samples are prone to find higher response rates than those 4 
in subsequent randomized studies (13). Overall, these shortcomings have well been 5 
exemplified in a systematic review of >3000 randomized clinical studies demonstrating 6 
that a total of 396 formerly established medical practices had been identified as lacking 7 
clinical benefit (14). 8 
While there are a few reported randomized controlled trials on ACC (Table 1), patient 9 
scarcity and high resource demand has limited the use of this method. As a 10 
consequence, among the 25 recommendations with evidence rating in the recent ACC 11 
guidelines by the European Society for Endocrinology and ENSAT, none were 12 
considered to have strong underlying evidence and only three were graded as having 13 
moderate evidence (5). Currently, there is only one randomized clinical trial active 14 
within the space of ACC: Mitotane With or Without Cisplatin and Etoposide After 15 
Surgery in Treating Participants With Stage I-III ACC With High Risk of Recurrence 16 
(ADIUVO-2, NCT03583710). This study has been designed to be executed within a 17 
clinical environment but has yet to be directly integrated into an established patient 18 
registry. This sets the stage for further optimization of the clinical trial method for the 19 
study of ACC in order to further improve clinical evidence and refine patient care. 20 
 21 
Registry-based clinical trials 22 
A randomized registry-based clinical trial is a prospective study using a clinical registry 23 
for patient identification, trial conduct and outcomes reporting. The registry-based 24 
randomized clinical trial maintains the strengths of a prospective clinical study, 25 
including high internal validity, stringent patient stratification, randomization to ensure 26 
unbiased study of interventions and analysing patient outcomes to determine the effect 27 
of the studied intervention (7, 9, 15). In variance to conventional trials, registry-based 28 
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studies provide the opportunity to lower costs and ensure more rapid patient inclusion 1 
(7, 9, 15). This method is particularly suitable for evaluation of interventions that are 2 
already established within the field, with documented data on adverse events and that 3 
does not require additional evaluations than those already performed within standard 4 
clinical practice.  5 
 6 
A registry structure can be used to identify eligible patients, randomize between 7 
different interventions, provide follow-up data and evaluate outcomes. To remain 8 
resource-effective, addition of procedures beyond standard clinical practice should be 9 
avoided. Experience from cardiovascular research has demonstrated that registry-10 
based clinical studies can be performed with more than 90% cost-saving compared to 11 
conventional trials (7, 9). On-going developments of this method include refinements 12 
of both biostatistical analysis and interpretation (16).  13 
 14 
To our knowledge, there are no reported registry-based clinical trials and only a few 15 
on-going within the field of medical oncology or endocrinology. In a review by Foroughi 16 
and colleagues, on-going registry-based clinical trials were described (9) from which 17 
we select two relevant examples: 18 
ALT-TRACC (17) is a phase II clinical trial randomizing patients with treatment naïve 19 
metastatic colorectal cancer between alternating oxaliplatin and irinotecan doublet 20 
schedules (experimental arm) versus continuous doublet chemotherapy (control arm). 21 
Primary objective is to evaluate the feasibility of conducting a multi-center, prospective, 22 
registry-based randomized clinical trial. The primary endpoint is recruitment rate. 23 
Secondary objectives focus on both efficacy and toxicity by collecting data from 24 
medical records and other data collection tools. The aim is to estimate progression 25 
free survival and radiological response rates. The study is based on the Treatment of 26 
Recurrent and Advanced Colorectal Cancer registry (9). 27 
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EX-TEM (18) is a phase III trial randomizing patients with newly diagnosed 1 
glioblastoma to six (control arm) versus twelve (experimental arm) cycles of post-2 
radiation temozolomide chemotherapy. The primary objective is to study treatment 3 
efficacy and the primary endpoint is overall survival. Secondary endpoints include 4 
adverse events and the necessity for temozolomide dose modification determined by 5 
data recorded in the medical records. The study makes usage of the Brain Registry 6 
Australia: Innovation and Translation registry (9). 7 
 8 
Current and previous randomized trials for ACC 9 
An overview of randomized clinical studies on ACC is provided in Table 1. FIRM-ACT 10 
was the first randomized study performed on ACC and compared the efficacy of a 11 
chemotherapy combination (etoposide, cisplatin and doxorubicin, EDP) plus mitotane 12 
versus streptozocin plus mitotane in the advanced setting (19). It reported a hazard 13 
ratio of 0.55 (95% Confidence Interval (CI) 0.43-0.69) in favour for EDP plus mitotane 14 
for progression free survival. Survival was not significantly different, hazard ratio 0.79 15 
(95% CI 0.61-1.02) in favour for EDP + mitotane. Quality of Life according the EORTC 16 
QLQ-C30 questionnaire revealed no changes at follow-up compared to baseline for 17 
the two treatment arms. 18 
As recruitment within the FIRM-ACT protocol had been achieved, it was quickly 19 
followed by GALACCTIC, a randomized phase III trial of linsitinib (inhibitor of IGF-1R 20 
and the insulin receptor) versus placebo for locally advanced or metastatic ACC (20). 21 
No difference in overall survival between linsitinib and placebo was noted, HR 0.94 22 
(95% CI 0.61-1.44). This study did, however, provide valuable information on the 23 
behaviour of untreated metastatic ACC progressive after mitotane therapy. In the 24 
control arm, median survival was 356 days (95% CI 249–556) while the disease control 25 
rate was 34.7% (95% CI 21.7–49.6) at 6 weeks and 8.2% at 12 weeks.  26 
There are currently two on-going randomized trials on ACC, both in the adjuvant 27 
setting (Table 1), mitotane versus follow-up in low to intermediate risk ACC (ADIUVO 28 
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study) and mitotane versus mitotane plus cisplatin and etoposide (ADIUVO-2 study) in 1 
high risk ACC. These trials will be fundamental to evaluate current practices for 2 
adjuvant therapy that are currently supported by retrospective data (21). 3 
 4 
The European Network for the Study of Adrenal Tumours 5 
The European Network for the Study of Adrenal Tumours was formally established in 6 
2002 through a merger of three already existing national networks on adrenal 7 
research: COMETE in France, GANIMED in Germany, and NISGAT in Italy with further 8 
teams joining in from the United Kingdom. In 2009, ENSAT became a membership-9 
based society with statutes and by-laws. An increasing number of researchers and 10 
health workers have joined in the efforts of the ENSAT with currently 479 members 11 
from 35 different countries. The European Network for the Study of Adrenal Tumours 12 
has structured its operation under four different working groups by disease subtype: 13 
ACC, pheochromocytoma and paraganglioma, aldosterone-producing adenoma and 14 
non-aldosterone producing cortical adrenal adenomas. Through its patient registry, the 15 
largest body of clinical annotations and biospecimens from patients with adrenal 16 
tumours has been aggregated (22). Currently (April 2020) it includes data from 17,680 17 
patients of 107 institutions, representing 33 predominantly European countries. A long 18 
list of disease specific clinical annotations has been collected. Current limitations of 19 
the ENSAT registry include its non-consecutive patient enrolment and lack of quality 20 
control. 21 
Based on the information reviewed in previous sections, we hypothesized that registry-22 
based trials would be a potential new tool to allow for more efficient studies on adrenal 23 
tumours. We hypothesized further that ENSAT would be ideally positioned to 24 
implement this technology as it already forms a strong network with large patient 25 
populations and operates a prospective registry. Finally, ACC was identified as the 26 
most suitable patient population among adrenal tumours to be evaluated in a pilot 27 
project due to large unmet needs in combination with up-to-date clinical practice 28 
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guidelines and potentially relevant study endpoint already available in the registry (5, 1 
23). 2 
 3 
The ENSAT ACC registry 4 
Currently, the ACC database includes data from 3,835 patients from 63 institutions 5 
(April 2020). It is structured under the following sections; diagnostic procedures (34 6 
variables), tumour staging (16 variables), biomaterial (20 variables), 7 
chemoembolization (four variables), chemotherapy (seven variables), follow-up (18 8 
variables), metabolomics (two variables), mitotane (nine variables), pathology (20 9 
variables), radiofrequency (five variables), radiotherapy (eight variables) and surgery 10 
(six variables). In total, these comprehensive data can be used to study endpoints 11 
relevant for patients with ACC; overall survival, recurrence free survival, progression 12 
free survival (accordingly to local analysis, but no specific protocol for radiological 13 
evaluation is requested, yet) and early discontinuation of medical therapy. Furthermore, 14 
appropriate factors for disease characterization can be used as inclusion / exclusion 15 
criteria as well as being incorporated into a future randomization module.   16 
 17 
Assessing the potential for registry-based clinical trials within ENSAT 18 
Two online surveys as well as discussions at scientific meetings had been conducted 19 
to determine the potential of registry-based clinical trials to be performed within the 20 
ENSAT community (Supplementary materials and methods). In a first survey 21 
(Supplementary table 1) responses had been collected from eighty-six members, 22 
including 66 full members and 20 associate members. The respondents represented 23 
22 different countries; Italy (n=22), Germany (n=10), France (n=8), Greece (n=7), 24 
United Kingdom (n=7), Netherlands (n=6) and Spain (n=4) being the most frequent. 25 
The high interest for registry-based clinical trials in ACC was reflected not only in the 26 
active participation in online surveys and real life meetings, but was also expressed 27 
directly in the surveys through the rated scientific potential, mean score 4.5 (maximum 28 
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5), and the anticipation to collaborate and contribute, with a mean rating of 4.3 1 
(maximum 5). 2 
General topics for ENSAT registry-based trials were proposed with positive/negative 3 
response options available (Figure 1A); evaluation of drugs or other medical 4 
interventions (90% positive), evaluation of prognostic or predictive biomarkers for 5 
therapeutic stratification (89% positive), prospective collection of clinical data and/or 6 
bio samples (71% positive), and comparison of different follow-up strategies (69% 7 
positive). Study participants were also asked, which ACC patient population should 8 
primarily be addressed (positive/negative response options available); neo-adjuvant 9 
setting (75% positive), adjuvant setting (87% positive) and advanced disease (61% 10 
positive). Next, survey participants were asked if they would foresee legal or any other 11 
administrative challenges related to registry-based clinical trials, which was answered 12 
with yes in 56% of cases with eight free text comments provided. Among these 13 
responses, reluctance from ethical review boards to provide ethical permissions were 14 
specifically mentioned. Another example demonstrating the strong interest in registry-15 
based clinical trials could be noted in the active discussion of particular scientific 16 
projects: There were a total of 48 different research projects being proposed. The 17 
ENSAT ACC working group scientific board prioritized these projects based on 18 
scientific quality and feasibility for further evaluation. 19 
In the subsequent survey (Supplementary table 2) there were 62 respondents, 50 full 20 
members and 12 associate members. These represented 19 different countries with 21 
Italy (n=19), France (n=6), Germany (n=6), Greece (n=5) and the United Kingdom 22 
(n=5) as the most frequent. A total of 87% of responders phrased the expectation that 23 
a registry-based clinical trial would be accepted by the local ethical committee, with 24 
eight additional comments in free text. In the next question, 43% assumed that 25 
randomization of study sites to different interventions ("cluster randomization") would 26 
be more likely to be acceptable to ethical review boards compared to randomization of 27 
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individual patients. Furthermore, concrete ideas for problems to be addressed within 1 
an ENSAT registry-based platform were collected. 2 
 3 
Proposal for registry-based studies on ACC based on the ENSAT platform 4 
Of the 48 different research projects being proposed by the ENSAT ACC working 5 
group, the scientific board and its members had previously selected and prioritized the 6 
following projects that gained particularly high scoring based on scientific value and 7 
feasibility (Figure 1B): 8 
 9 
Adjuvant setting - Comparison of different durations of mitotane treatment for 10 
effectiveness and toxicity. Adjuvant treatment with mitotane is recommended in 11 
patients without macroscopic residual tumour after surgery who have a perceived high 12 
risk of recurrence (5, 21, 24). However, the optimal duration of mitotane treatment, to 13 
balance efficacy and adverse effects of the compound is currently unknown. Therefore, 14 
a randomized controlled study between a duration of e.g. 2 vs. 5 years of mitotane 15 
treatment would be informative. 16 
Advanced ACC I - Comparison of different first-line chemotherapy protocols for 17 
effectiveness and toxicity. The most validated first-line treatment option for 18 
unresectable and advanced ACC is the combination of etoposide, doxorubicin, 19 
cisplatin, and mitotane (EDP-M) (19). Treatment with EDP-M comes with a risk of 20 
adverse events. Based on small trials (25, 26) and individual experience (5) it has been 21 
hypothesized that omitting doxorubicin from the treatment protocol would increase 22 
tolerability without a clinically relevant loss of efficacy. This hypothesis could be 23 
evaluated through a randomized controlled study between EDP-M (standard arm) 24 
versus etoposide, cisplatin and mitotane (experimental arm). 25 
Advanced ACC II - Comparison of anti-tumour efficacy of mitotane at different 26 
concentrations. It is believed that mitotane toxicity and efficacy is strongly correlated 27 
to plasma levels of the compound (27-29). It has been hypothesized that by lowering 28 
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the therapeutic concentration target for mitotane in advanced ACC, patients would 1 
experience less treatment related toxicity. This could potentially result in improved 2 
quality of life without clinically significant loss in efficacy. For this purpose, a 3 
randomized controlled study between standard therapy aiming at a mitotane blood 4 
level > 14 mg/L (standard arm) versus a mitotane regime aiming at lower concentration 5 
(e.g. > 10 mg/L; experimental arm) would lead to clinically important information. 6 
Potential objectives to be investigated in these three proposals include the evaluation 7 
of recruitment feasibility, quality of data capture, patient benefit in terms of overall 8 
survival and quality of life as well as drug tolerability. Furthermore, we propose that 9 
quality of life could be measured through patient self-reporting through a web-based 10 
application (currently not available in the ENSAT registry). In addition, safety could be 11 
described from the documentations made in the patient records. We also argue that 12 
both cluster and patient randomization could be used to address these three research 13 
questions. The studies could also be designed as superiority and/or non-superiority 14 
trials, all depending on what primary endpoint is finally selected. 15 
 16 
In addition to studying different interventions, we envision the possibility to execute 17 
prospective longitudinal observation studies to collect information and biomaterial on 18 
predictive markers of treatment response as well as prognostic factors. The underlying 19 
rationale comes from the rapid advances in our understanding of the biology of ACC 20 
(1, 30-35), which translates into a need for efficient test beds to evaluate new 21 
biomarkers for different clinical purposes.  22 
 23 
Challenges 24 
Examples in clinical cardiovascular research has provided a clear proof of concept of 25 
how a strong network can be enhanced to perform registry-based clinical trials through 26 
technical advances of the current infrastructure but only minor changes in clinical and 27 
research practice (7). One potential factor limiting the dissemination of registry-based 28 
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trials could be legal and administrative restrictions. In our surveys, a high proportion of 1 
participants (87%) anticipated acceptance of a registry-based trial by their local ethical 2 
review boards. However, as the registry-based randomized trial is a concept currently 3 
lacking a clear definition it is expected to be treated with the same level of scrutiny as 4 
conventional clinical trials. This will impose rules and regulations not applicable to 5 
registry based randomized trials. As such, the current legislative environment needs 6 
to be adopted to fit randomized registry-based clinical trials in order to ensure a lower 7 
complexity that will otherwise increase costs. 8 
While the foundation for a future infrastructure for registry-based trails exist 9 
within ENSAT, additional method development will be required including a 10 
randomization module as well as the possibility for source data verification (Figure 2). 11 
There is also a need for data monitoring to ensure high validity of the data within the 12 
registry. Furthermore, our work also raised the potential to implement clinical decision 13 
support, active suggestion of potential research studies and integration with patient 14 
self-reporting into the ENSAT registry. While such infrastructure upgrades are all 15 
technically feasible, additional resources will be necessary for its implementation. And 16 
as this research direction is pursued in other medical settings, ENSAT could potentially 17 




The ENSAT ACC community has expressed a strong interest and support of in 22 
registry-based trials as a new infrastructure with potential to significantly advance care 23 
for patients with this rare disease. This review summarises the scientific foundation for 24 
this research direction and outlines potential questions to be addressed within such a 25 
new infrastructure and provides a roadmap for future pilot projects. 26 
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Table 1. Randomized studies in ACC 1 










































































* Secondary endpoints also included, 1) Identification of clinical and pathological predictors of recurrence, and 2) Stratification of results by 2 
mitotane levels.  3 
ACC, Adrenocortical Carcinoma; ADIUVO, Efficacy of Adjuvant Mitotane Treatment; ADIUVO-2, Mitotane With or Without Cisplatin and Etoposide 4 
After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence; FIRM-ACT, Trial in Locally Advanced 5 
- 2 - 
and Metastatic Adrenocortical Carcinoma Treatment; GALACCTIC, A Study of OSI-906 in Patients With Locally Advanced or Metastatic 1 
Adrenocortical Carcinoma; OS, Overall survival; PFS, Progression Free Survival; QoL, Quality of Life.2 
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with documented safety 
profiles 
Capacity to include 
complex criteria and 
outcome measures 
including adverse events 
Patient criteria and 
outcome factors less 
detailed and limited to 
existing registry 
Highly selected patient 
populations 
Broad and representative 
patient populations 
Ensured high validity and 
data quality through 
monitoring 
Validity and data quality 




High cost Low cost 
Executed within a 
dedicated environment 
separate to standard 
clinical care 
Uses established clinical 
infrastructure. Integration 
with existing high quality 
registries mandatory. 
Individual identification of 
suitable candidates 
Registry may facilitate 
integrated identification of 
suitable patients 
Demanding to achieve 
fast patient inclusion 
More rapid patient 
inclusion rate due to 
broad eligibility and wide 
dissemination of centers 
Regulatory environment 
adopted to conventional 
trials 
Regulatory environment 
not adopted to the 
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Figure Legends 
Figures 1A-B 
Selected data from surveys 1 and 2 demonstrating different research topics where a 
registry-based trial infrastructure was proposed to provide value to patients with 
adrenocortical carcinoma. ACC, Adrenocortical carcinoma; EDP, Etoposide + 
doxorubicin + platinum based chemotherapy; EP, etoposide + platinum based 
chemotherapy. 
Figure 2 
Unmet needs of the European Network for the Study of Adrenal Tumours database in 
order to advance research and perform efficient randomized registry-based trials.  
